Transperineal magnetic resonance imaging–targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer …
The diagnostic accuracy of magnetic resonance imaging (MRI)-targeted biopsy by using the
transperineal (TP) versus transrectal (TR) route in the detection of clinically significant …
transperineal (TP) versus transrectal (TR) route in the detection of clinically significant …
Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound
A Mortezavi, J Krauter, A Gu, J Sonderer… - The Journal of …, 2019 - auajournals.org
Purpose: Clinically significant, localized prostate cancer is currently treated with whole gland
therapy. This approach is effective but associated with genitourinary and rectal side effects …
therapy. This approach is effective but associated with genitourinary and rectal side effects …
Histopathological to multiparametric MRI spatial mapping of extended systematic sextant and MR/TRUS-fusion-targeted biopsy of the prostate
D Bonekamp, P Schelb, M Wiesenfarth, TA Kuder… - European …, 2019 - Springer
Purpose MRI has limited ability to detect multifocal disease or the full extent of prostate
involvement with clinically significant prostate cancer (sPC). We compare the spatial co …
involvement with clinically significant prostate cancer (sPC). We compare the spatial co …
How many cores should be obtained during saturation biopsy in the era of multiparametric magnetic resonance? Experience in 875 patients submitted to repeat …
P Pepe, M Pennisi, F Fraggetta - Urology, 2020 - Elsevier
Objective To evaluate the number of needle cores combined with multiparametric magnetic
resonance imaging (mpMRI) findings needed to diagnose all clinically significant cases of …
resonance imaging (mpMRI) findings needed to diagnose all clinically significant cases of …
Early second round targeted biopsy of PI-RADS score 3 or 4 in 256 men with persistent suspicion of prostate cancer
P Pepe, A Garufi, GD Priolo, M Pennisi, F Fraggetta - in vivo, 2019 - iv.iiarjournals.org
Background/Aim: The aim of the study was to determine the rate of clinically significant
prostate cancer (csPCa) cases in men submitted to early second round mpMRI/TRUS …
prostate cancer (csPCa) cases in men submitted to early second round mpMRI/TRUS …
A narrative review and update on management following negative prostate biopsy
DC Cheung, J Li, A Finelli - Current Opinion in Urology, 2018 - journals.lww.com
Management following an initial negative prostate biopsy requires careful discussion with
the patient, their risk tolerance, and threshold for intervention. Although subject to …
the patient, their risk tolerance, and threshold for intervention. Although subject to …
[PDF][PDF] Das Prostatakarzinom–Screening, Diagnostik und Therapie
D Eberli, B Kranzbühler - … und Mammakarzinom: Screening und Therapie sowie … - svv.ch
In der Schweiz ist das Prostatakarzinom die bei Männern häufigste Tumorerkrankung und
die zweithäufigste tumorbedingte Todesursache nach dem Bronchialkarzinom. Pro Jahr …
die zweithäufigste tumorbedingte Todesursache nach dem Bronchialkarzinom. Pro Jahr …